Idiopathic Intracranial Hypertension Clinical Trial
Official title:
An Exploratory Study Assessing the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment
This study aims to investigate the safety and efficacy of semaglutide in patients with Idiopathic intracranial hypertension.
Idiopathic intracranial hypertension (IIH) is a condition characterized by elevated pressure within the skull for reasons that are not yet understood. This condition does not involve abnormalities in the cerebrospinal fluid or any structural brain damage. Individuals with this condition commonly experience persistent headaches, and some may face the potential of irreversible vision loss, significantly impacting their psychological well-being and overall quality of life. At present, the efficacy of medications like acetazolamide and topiramate in managing IIH is constrained by practical clinical constraints. Recent studies have indicated that glucagon-like peptide-1 receptor agonists show promise as a potential treatment option for IIH. Semaglutide, as a long-acting glucagon-like peptide-1 formulation, has a half-life of up to 160 hours and only needs to be injected once a week. It is easy to administer and has good safety and tolerability. Hence, the objective of this study is to investigate the effectiveness and safety of semaglutide in managing idiopathic intracranial hypertension, laying the groundwork for subsequent extensive, multicenter research endeavors. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01863381 -
Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement
|
N/A | |
Recruiting |
NCT06027567 -
The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
|
Phase 4 | |
Active, not recruiting |
NCT02896452 -
Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome
|
||
Recruiting |
NCT06059703 -
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension
|
N/A | |
Terminated |
NCT05347147 -
A Trial to Determine the Efficacy and Safety of Presendin in IIH
|
Phase 3 | |
Active, not recruiting |
NCT02124486 -
An RCT of Bariatric Surgery vs a Community Weight Loss Programme for the Sustained Treatment of IIH
|
N/A | |
Recruiting |
NCT02143258 -
Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension
|
N/A | |
Enrolling by invitation |
NCT05308823 -
Outcome of Cerebral Venous Sinuses Stenting on Idiopathic Intracranial Hypertension
|
N/A | |
Not yet recruiting |
NCT05762367 -
MR Lymphatic Imaging in Idiopathic Intracranial Hypertention
|
N/A | |
Not yet recruiting |
NCT06436820 -
ICP & Outflow Study
|
||
Completed |
NCT03867461 -
The Effects of MAP and EtCO2 on Venous Sinus Pressures
|
N/A | |
Completed |
NCT03963336 -
Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension
|
Early Phase 1 | |
Completed |
NCT01003639 -
Idiopathic Intracranial Hypertension Treatment Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT03096743 -
Evaluating Raised Intracranial Pressure Using MR Elastography
|
N/A | |
Completed |
NCT04314128 -
Assessment of ICP in Idiopathic Intracranial Hypertension Using Transocular Ultrasound and Transcranial Doppler
|
N/A | |
Terminated |
NCT03501966 -
Surgical Idiopathic Intracranial Hypertension Treatment Trial
|
Phase 3 | |
Active, not recruiting |
NCT03556085 -
Venous Sinus Stenting With the River Stent in IIH
|
N/A | |
Completed |
NCT02017444 -
Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.
|
Phase 2 |